These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23475691)

  • 1. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.
    Cappelleri JC; Bushmakin AG; Harness J; Mamolo C
    Qual Life Res; 2013 Nov; 22(9):2489-99. PubMed ID: 23475691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.
    Callis Duffin K; Bushmakin AG; Cappelleri JC; Mallbris L; Mamolo C
    BMC Dermatol; 2019 Jun; 19(1):8. PubMed ID: 31174539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
    Bushmakin AG; Mamolo C; Cappelleri JC; Stewart M
    J Dermatolog Treat; 2015 Feb; 26(1):19-22. PubMed ID: 24289224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
    Burden AD; Bissonnette R; Anatchkova M; Budhiarso I; Skalicky AM; Liberato ACS; Hu N; Thoma C; Gloede T; Kohlmann T; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1383-1390. PubMed ID: 38334243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
    Yu N; Peng C; Zhou J; Gu J; Xu J; Li X; Bi X; Deng H; Li X; Ding Y; Shi Y
    Br J Dermatol; 2023 Sep; 189(4):437-446. PubMed ID: 37310289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
    Ständer S; Luger T; Cappelleri JC; Bushmakin AG; Mamolo C; Zielinski MA; Tallman AM; Yosipovitch G
    Acta Derm Venereol; 2018 Mar; 98(3):340-345. PubMed ID: 29182790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).
    Burden AD; Bissonnette R; Lebwohl MG; Gloede T; Anatchkova M; Budhiarso I; Hu N; Thoma C; Skalicky AM; Bachelez H
    J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1327-1335. PubMed ID: 36854864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
    Gottlieb AB; Warren RB; Augustin M; Garcia L; Cioffi C; Peterson L; Pelligra C; Ciaravino V
    Adv Ther; 2021 Oct; 38(10):5253-5269. PubMed ID: 34471992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
    Abe M; Nishigori C; Torii H; Ihn H; Ito K; Nagaoka M; Isogawa N; Kawaguchi I; Tomochika Y; Kobayashi M; Tallman AM; Papp KA
    J Dermatol; 2017 Nov; 44(11):1228-1237. PubMed ID: 28714180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
    Bożek A; Reich A
    Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
    Langley RG; Ellis CN
    J Am Acad Dermatol; 2004 Oct; 51(4):563-9. PubMed ID: 15389191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
    Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
    Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
    BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
    Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
    J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
    Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
    J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment.
    Simpson MJ; Chow C; Morgenstern H; Luger TA; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1415-20. PubMed ID: 25917214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.